Whistleblower To Receive $562,370 For Exposing Disadvantaged Business Enterprise Program Fraud

False Claims Act, Whistleblower

TesTech, Inc.,  CESO Testing Technology, Inc., CESO International, LLC, and CESO, Inc. have agreed to pay $2,883,947 to resolve allegations that they falsely claimed disadvantaged business status on a number of federally-funded transportation projects. The Department...

Whistleblower Lawsuits Lead To $33.5 Million Taxpayer Recovery In Misbranded Drug Case

False Claims Act, Whistleblower

ISTA Pharmaceuticals, Inc. has pled guilty to felony charges relating to its marketing of Xibrom, an anti-inflammatory drug that was approved by the FDA to treat pain and inflammation following cataract surgery.  The criminal charges arise from violations of the Food,...

False Claims Act Lawsuit Leads To $7.3 Million U.S. Taxpayer Recovery

False Claims Act, Whistleblower

U.S. Renal Care has agreed to pay $7.3 million to resolve a whistleblower lawsuit alleging that it overcharged the Medicare program for Epogen administered to dialysis patients at facilities operated by Dialysis Corporation of America (DCA).  U.S. Renal Care acquired...

C.R. Bard Inc. To Pay $48.26 Million To Resolve False Claims Act Lawsuit

False Claims Act, Whistleblower

C.R. Bard Inc. has agreed to pay $48.26 million to resolve allegations that it knowingly caused false claims to be submitted to the Medicare program for brachytherapy seeds used to treat prostate cancer in violation of the False Claims Act. This case was initiated by...

Generic Drug Manufacturer Ranbaxy Pleads Guilty And Agrees To Pay $500 Million To Resolve False Claims Allegations Raised In Whistleblower Lawsuit

False Claims Act, Whistleblower

Ranbaxy USA Inc., a subsidiary of Indian generic pharmaceutical manufacturer Ranbaxy Laboratories Limited, pleaded guilty to charges relating to the manufacture and distribution of adulterated drugs made at two of its facilities.  In addition to its guilty plea,...